Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

Open-angle Glaucoma

Ocular Hypertension

ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice

IOP is a measurement of the fluid pressure inside the study eye. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.

Time to first IOP-lowering intervention is defined as the time between treatment and IOP-lowering intervention.

A numerical count by class of drug of topical IOP lowering medications being taken.

Complete success is defined as treated eyes with IOP <=18 mm Hg without any additional IOP lowering interventions/therapies after administration of the bimatoprost intracameral implant.

Partial success is defined as treated eyes with IOP <=18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).

Partial success is defined as treated eyes with IOP ≤18 mm Hg with no Secondary Surgical Intervention (SSI) for glaucoma, while staying on the same or fewer topical IOP-lowering medications than baseline and or Selective Laser Trabeculoplasty (SLT), Argon Laser Trabeculoplasty (ALT) or MicroPulse Laser Trabeculoplasty (MLT).

Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.

Angeles Eye Institute /ID# 240368

Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240364

American Institute of Research /ID# 247820

North Bay Eye Associates Inc. /ID# 240362

Pacific Eye Associates /ID# 240536

Colorado Eye Institute /ID# 240798

ICON Eye Care /ID# 240681

Eye Associates of Fort Meyers /ID# 244476

MedEye Associates /ID# 240374

Center for Sight - Sarasota /ID# 244578

Newsom Eye & Laser Center /ID# 253287

Dr. Andrew Gardner Logan, FL /ID# 240361

Your Eye Specialists /ID# 253286

Georgia Eye Partners /ID# 240061

Kovach Eye Institute /ID# 244581

Stiles Eyecare Excellence /ID# 240376

The Eye Care Institute /ID# 240367

John Hopkins Wilmer Eye Institute /ID# 243701

Midwest Vision Research Foundation at Pepose Vision Institute /ID# 240537

Wiles Eye Center /ID# 240808

Ophthalmology Associates /ID# 240799

Eye Associates of North Jersey /ID# 244585

Hudson Eye /ID# 240805

Glaucoma Care Center /ID# 252021

Burlington County Eye Physicians /ID# 244594

MaculaCare PLLC /ID# 244593

New York New Jersey Eye Institute /ID# 244590

New York Eye Surgery Associates, PLLC /ID# 244592

Duke Eye Center /ID# 244478

Bergstrom Eye Research LLC /ID# 240363

META Medical Research Institute, LLC /ID# 240800

Oklahoma Eye Surgeons /ID# 240373

Scott and Christie and Associates /ID# 244574

Vanderbilt University Medical Center /ID# 244577

Glaucoma Associates of Texas /ID# 240682

Glaucoma Associates of Texas /ID# 253289

El Paso Eye Surgeons, P.A. /ID# 240366

DCT Shah Eye Research Institut /ID# 240375

The Eye Centers of Racine and Kenosha LTD /ID# 240059

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

About this trial

Study ID

Status

Type

Placebo

Accepting

Trial Timing

What is this trial about?

What are the participation requirements?